CLRB240719C7500
- 0.03
- 0.000.00%
Cellectar BioSciences Newsroom
Cellectar Biosciences to Host Key Opinion Leader Event to Review the Full Results From Its CLOVER WaM Pivotal Trial and Waldenstrom's Macroglobulinemia Market Landscape
FLORHAM PARK, N.J., June 27, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for
Cellectar Biosciences and City of Hope Cancer Center Enter Collaboration to Assess Iopofosine I 131 in Mycoid Diseases
Cellectar Biosciences and City of Hope Cancer Center Enter Collaboration to Assess Iopofosine I 131 in Mycoid Diseases
Express News | Cellectar Biosciences and City of Hope Cancer Center Enter Collaboration to Evaluate Iopofosine I 131 in Mycosis Fungoides
Cellectar Biosciences Inc files for up to $300 million hybrid shelf — SEC filing
Cellectar Biosciences Inc files for up to $300 million hybrid shelf — SEC filing
Express News | Cellectar Biosciences Inc Files for Mixed Shelf of up to $300 Mln - SEC Filing
Buy Rating on Cellectar Biosciences Backed by Strong Clinical Data and Promising Drug Pipeline
Q1 2024 Cellectar Biosciences Inc Earnings Call
Cellectar Biosciences Inc (CLRB) Q1 2024 Earnings Call Transcript Highlights: Strategic ...
Earnings Call Summary | Cellectar BioSciences(CLRB.US) Q1 2024 Earnings Conference
The following is a summary of the Cellectar Biosciences, Inc. (CLRB) Q1 2024 Earnings Call Transcript:Financial Performance:Cellectar Biosciences saw a significant increase in cash and cash equivalent
Cellectar Biosciences, Inc. (CLRB) Q1 2024 Earnings Call Transcript
Cellectar Biosciences, Inc. (CLRB) Q1 2024 Earnings Call Transcript
Cellectar Biosciences Inc Loss At -$21.58 Mln In Q1
Cellectar Biosciences' Cash and Cash Equivalents, As of March 31, 2024, Was $40M That Is Expected To Provide Cash Runway Into Fourth Quarter Of 2024
Cellectar Biosciences' Cash and Cash Equivalents, As of March 31, 2024, Was $40M That Is Expected To Provide Cash Runway Into Fourth Quarter Of 2024
Cellectar Biosciences (CLRB.US): The 2024 Q1 financial report achieved revenue of $0, previous value of $0; earnings per share were -0.74 dollars, previous value was -0.76 dollars, and expected value was -0.72 dollars.
Cellectar Biosciences (CLRB.US): The 2024 Q1 financial report achieved revenue of $0, previous value of $0; earnings per share were -0.74 dollars, previous value was -0.76 dollars, and expected value was -0.72 dollars.
Press Release: Cellectar Biosciences Reports Financial Results for Q1 2024 and Provides a Corporate Update
Cellectar Biosciences Reports Financial Results for Q1 2024 and Provides a Corporate Update Management to host a conference call today at 8:30 am ET WM pivotal study data to be announced in June FL
Cellectar Biosciences 1Q Loss/Shr 74c >CLRB
Cellectar Biosciences 1Q Loss/Shr 74c >CLRB
Cellectar Biosciences Q1 2024 GAAP EPS $(0.74) Misses $(0.56) Estimate
Cellectar Biosciences Q1 2024 GAAP EPS $(0.74) Misses $(0.56) Estimate
Cellectar BioSciences | 10-Q: Quarterly report
Cellectar Biosciences Q1 2024 Earnings Preview
Cellectar Biosciences to Present at the Guggenheim Healthcare Talks Radiopharmaceuticals Day
FLORHAM PARK, N.J., May 08, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercial
Cellectar Biosciences to Announce First Quarter Financial Results and Host a Conference Call on Tuesday, May 14, 2024
FLORHAM PARK, N.J., May 07, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of drugs for